214 related articles for article (PubMed ID: 21865047)
1. 6,7-Dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidines and their derivatives as novel corticotropin-releasing factor 1 receptor antagonists.
Saito T; Obitsu T; Kondo T; Matsui T; Nagao Y; Kusumi K; Matsumura N; Ueno S; Kishi A; Katsumata S; Kagamiishi Y; Nakai H; Toda M
Bioorg Med Chem; 2011 Sep; 19(18):5432-45. PubMed ID: 21865047
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines as potent CRF1 receptor antagonists.
Huang CQ; Wilcoxen KM; Grigoriadis DE; McCarthy JR; Chen C
Bioorg Med Chem Lett; 2004 Aug; 14(15):3943-7. PubMed ID: 15225703
[TBL] [Abstract][Full Text] [Related]
3. Pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a]pyrimidines and their tricyclic derivatives as corticotropin-releasing factor 1 (CRF₁) receptor antagonists.
Saito T; Obitsu T; Minamoto C; Sugiura T; Matsumura N; Ueno S; Kishi A; Katsumata S; Nakai H; Toda M
Bioorg Med Chem; 2011 Oct; 19(20):5955-66. PubMed ID: 21930387
[TBL] [Abstract][Full Text] [Related]
4. Cyclopenta[d]pyrimidines and dihydropyrrolo[2,3-d]pyrimidines as potent and selective corticotropin-releasing factor 1 receptor antagonists.
Arban R; Benedetti R; Bonanomi G; Capelli AM; Castiglioni E; Contini S; Degiorgis F; Di Felice P; Donati D; Fazzolari E; Gentile G; Marchionni C; Marchioro C; Messina F; Micheli F; Oliosi B; Pavone F; Pasquarello A; Perini B; Rinaldi M; Sabbatini FM; Vitulli G; Zarantonello P; Di Fabio R; St-Denis Y
ChemMedChem; 2007 Apr; 2(4):528-40. PubMed ID: 17335099
[TBL] [Abstract][Full Text] [Related]
5. Optimization of 3-phenylpyrazolo[1,5-a]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility.
Chen C; Wilcoxen KM; Huang CQ; McCarthy JR; Chen T; Grigoriadis DE
Bioorg Med Chem Lett; 2004 Jul; 14(14):3669-73. PubMed ID: 15203140
[TBL] [Abstract][Full Text] [Related]
6. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
Chen C; Wilcoxen KM; Huang CQ; Xie YF; McCarthy JR; Webb TR; Zhu YF; Saunders J; Liu XJ; Chen TK; Bozigian H; Grigoriadis DE
J Med Chem; 2004 Sep; 47(19):4787-98. PubMed ID: 15341493
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and SAR of 2-dialkylamino-4-arylpyrimidines as potent and selective corticotropin-releasing factor(1) (CRF(1)) receptor antagonists.
Huang CQ; Grigoriadis DE; Liu Z; McCarthy JR; Ramphal J; Webb T; Whitten JP; Xie MY; Chen C
Bioorg Med Chem Lett; 2004 May; 14(9):2083-6. PubMed ID: 15080983
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: a centrally active corticotropin-releasing factor1 receptor antagonist.
Chen YL; Mansbach RS; Winter SM; Brooks E; Collins J; Corman ML; Dunaiskis AR; Faraci WS; Gallaschun RJ; Schmidt A; Schulz DW
J Med Chem; 1997 May; 40(11):1749-54. PubMed ID: 9171885
[TBL] [Abstract][Full Text] [Related]
9. Heteroaryl-substituted 4-(1H-pyrazol-1-yl)-5,6-dihydro-1H-pyrrolo[2,3-d]pyrimidine derivatives as potent and selective corticotropin-releasing factor receptor-1 antagonists.
Sabbatini FM; Di Fabio R; St-Denis Y; Capelli AM; Castiglioni E; Contini S; Donati D; Fazzolari E; Gentile G; Micheli F; Pavone F; Rinaldi M; Pasquarello A; Zampori MG; Di Felice P; Zarantonello P; Arban R; Perini B; Vitulli G; Benedetti R; Oliosi B; Worby A
ChemMedChem; 2008 Feb; 3(2):226-9. PubMed ID: 18000940
[No Abstract] [Full Text] [Related]
10. Design, synthesis, and structure-activity relationships of novel pyrazolo[5,1-b]thiazole derivatives as potent and orally active corticotropin-releasing factor 1 receptor antagonists.
Takahashi Y; Hashizume M; Shin K; Terauchi T; Takeda K; Hibi S; Murata-Tai K; Fujisawa M; Shikata K; Taguchi R; Ino M; Shibata H; Yonaga M
J Med Chem; 2012 Oct; 55(19):8450-63. PubMed ID: 22971011
[TBL] [Abstract][Full Text] [Related]
11. Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats.
Lelas S; Wong H; Li YW; Heman KL; Ward KA; Zeller KL; Sieracki KK; Polino JL; Godonis HE; Ren SX; Yan XX; Arneric SP; Robertson DW; Hartig PR; Grossman S; Trainor GL; Taub RA; Zaczek R; Gilligan PJ; McElroy JF
J Pharmacol Exp Ther; 2004 Apr; 309(1):293-302. PubMed ID: 14742750
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of tricyclic corticotropin-releasing factor-1 antagonists.
Gross RS; Guo Z; Dyck B; Coon T; Huang CQ; Lowe RF; Marinkovic D; Moorjani M; Nelson J; Zamani-Kord S; Grigoriadis DE; Hoare SR; Crowe PD; Bu JH; Haddach M; McCarthy J; Saunders J; Sullivan R; Chen T; Williams JP
J Med Chem; 2005 Sep; 48(18):5780-93. PubMed ID: 16134945
[TBL] [Abstract][Full Text] [Related]
13. Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors.
Ducray R; Ballard P; Barlaam BC; Hickinson MD; Kettle JG; Ogilvie DJ; Trigwell CB
Bioorg Med Chem Lett; 2008 Feb; 18(3):959-62. PubMed ID: 18182285
[TBL] [Abstract][Full Text] [Related]
14. Pyrazolo[1,5-a]pyrimidine CRF-1 receptor antagonists.
Wustrow DJ; Capiris T; Rubin R; Knobelsdorf JA; Akunne H; Davis MD; MacKenzie R; Pugsley TA; Zoski KT; Heffner TG; Wise LD
Bioorg Med Chem Lett; 1998 Aug; 8(16):2067-70. PubMed ID: 9873487
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A adenosine receptor antagonists.
Baraldi PG; Cacciari B; Spalluto G; Bergonzoni M; Dionisotti S; Ongini E; Varani K; Borea PA
J Med Chem; 1998 Jun; 41(12):2126-33. PubMed ID: 9622554
[TBL] [Abstract][Full Text] [Related]
16. Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice.
Nielsen DM; Carey GJ; Gold LH
Eur J Pharmacol; 2004 Sep; 499(1-2):135-46. PubMed ID: 15363960
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.
Baraldi PG; Fruttarolo F; Tabrizi MA; Preti D; Romagnoli R; El-Kashef H; Moorman A; Varani K; Gessi S; Merighi S; Borea PA
J Med Chem; 2003 Mar; 46(7):1229-41. PubMed ID: 12646033
[TBL] [Abstract][Full Text] [Related]
18. 2-Arylpyrimidines: novel CRF-1 receptor antagonists.
Yoon T; De Lombaert S; Brodbeck R; Gulianello M; Krause JE; Hutchison A; Horvath RF; Ge P; Kehne J; Hoffman D; Chandrasekhar J; Doller D; Hodgetts KJ
Bioorg Med Chem Lett; 2008 Aug; 18(16):4486-90. PubMed ID: 18672365
[TBL] [Abstract][Full Text] [Related]
19. The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA(3) adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition.
Cheong SL; Dolzhenko A; Kachler S; Paoletta S; Federico S; Cacciari B; Dolzhenko A; Klotz KN; Moro S; Spalluto G; Pastorin G
J Med Chem; 2010 Apr; 53(8):3361-75. PubMed ID: 20307065
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of benzoylpyrimidines as antagonists of the corticotropin-releasing factor-1 receptor.
Webb TR; Moran T; Huang CQ; McCarthy JR; Grigoriadis DE; Chen C
Bioorg Med Chem Lett; 2004 Aug; 14(15):3869-73. PubMed ID: 15225687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
